ODTÜ Enformatik Enstitüsü'nün aylık Cuma Seminerlerinin ikinci konuşması ODTÜ Enformatik Enstitüsü Sağlık Bilişim Programından Prof. Dr. Rengül Çetin-Atalay tarafından verilecektir:
“Biyoinformatik Yoluyla Kanserde Kişiselleştirilmiş Tıp”.
Yer: Enformatik Enstitüsü Konferans Salonu 124
Zaman: 4 Mayıs 2018, 15:30-16:30.
This seminar is open to public and those outside METU have to register from here.
Abstract: Due to the recent advances in molecular biology and the applications of optoelectronic sensors, the volume of biological data in biomedical research has increased significantly. We now acquire large data sets which provides the novel insights for the biology of a disease, in particular for cancer which is recently reported as the most-deadly disease by WHO. The analysis of the molecular characteristics of a patient’s disease through computational tools allows patient stratification for better healthcare which is tailored for personalized prevention, diagnosis, and treatment. In this talk I will summarize recent advances on personalized cancer medicine with a special focus on related KanSiLab studies.
Short Bio: Dr. Rengul Cetin-Atalay holds MD degree and PhD degree in Systems Biology and her research falls in the broad fields of pathway analysis, bioinformatics and biomedical-image analysis and specifically in molecular cellular biology of primary liver cancer. She worked as a research assistant at Ecole Polytechnique, Paris, France during her PhD, and as an assistant professor at Virginia Bioinformatics Institute, Virginia Polytechnic Institute and State University (Virginia Tech), USA during her sabbatical leave in 2004. She is the recipient of several awards including Turkish Academy of Sciences Young Investigator Award (2002), UICC International Cancer Technology Transfer Award (2008), and Sanovel Pharmaceuticals Inc, Drug Research Award (2013). During the last decade, she extended her studies on the discovery of novel chemotherapeutics for liver cancer by the application of computational techniques on the analysis of pharmaco-transcriptomics data. Her experience in the interdisciplinary research approach in cancer biology with various aspects of this disease, devotes her research towards personalized medicine.